Ebola Threat Prompts EU To Focus On Adaptive Licensing
This article was originally published in The Pink Sheet Daily
Executive Summary
The spread of Ebola to Europe is prompting regulators and industry to explore in more detail adaptive licensing pathways to speed access to potentially life-saving drugs.
You may also be interested in...
U.K.’s NICE Plans Office To Help Drugs Gain Coverage Faster
NICE is responding to a government consultation on how the cost-effectiveness watchdog should update its methodologies and processes in evaluating new products by opening a new Office for Market Access, which it says will help life sciences companies prepare for its appraisals and better their chances for coverage.
European Notebook: Piloting Adaptive Pathways; Hepatitis C Pricing; IPO Window
The first six medicines are selected to pilot Europe’s speedier patient access scheme; France’s proposed health care reforms attract opposition, including a doctors' strike; European biotech companies expect a continuing funding stream from IPOs over the next 12 months.
Europe Mustering Its Scientific And Political Arsenal At Ebola And Beyond
The European Union and the EU drug industry have targeted over €1.25 billion for fighting Ebola, through research projects for vaccines, diagnostics and therapies, and direct aid to West Africa.